Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns

Nature Reviews Immunology

Volumn 10, Issue 11, 2010, Pages 787-796

  Bachmann, Martin F ^a   Jennings, Gary T ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ANTIGEN PRESENTING CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GEOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; KINETICS; MOLECULAR SIZE; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIGENS, VIRAL; HUMANS; VIRAL VACCINES; VIRUSES;

EID: 78049288264     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2868     Document Type: Review

References (119)

1. Fenner, F., Henderson, D., Arita, L., Jezek, Z. & Ladnyi, L. (eds) Smallpox and its eradication (WHO, Geneva, 1988).
2. Jennings, G. T. & Bachmann, M. F. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr. Mol. Med. 7, 143-155 (2007).
3. Walker, L. M. & Burton, D. R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22, 358-366 (2010).
4. Tissot, A. C. et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371, 821-827 (2008).
5. Cornuz, J. et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3, e2547 (2008).
6. Shi, Y. & Huang, G. Recent developments of biodegradable and biocompatible materials based micro/nanoparticles for delivering macromolecular therapeutics. Crit. Rev. Ther. Drug Carrier Syst. 26, 29-84 (2009).
7. Scheerlinck, J. P. & Greenwood, D. L. Virus-sized vaccine delivery systems. Drug Discov. Today 13, 882-887 (2008).
8. Zinkernagel, R. M. On natural and artificial vaccinations. Annu. Rev. Immunol. 21, 515-546 (2003).
9. Singh, M., Chakrapani, A. & O'Hagan, D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 6, 797-808 (2007).
10. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
11. Pozzi, L. A., Maciaszek, J. W. & Rock, K. L. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J. Immunol. 175, 2071-2081 (2005).
12. Ahsan, F., Rivas, I. P. , Khan, M. A. & Torres Suarez, A. I. Targeting to macrophages: role of physicochemical properties of particulate carriers liposomes and microspheres on the phagocytosis by macrophages. J. Control. Release 79, 29-40 (2002).
13. Bottazzi, B., Doni, A., Garlanda, C. & Mantovani, A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28, 157-183 (2010).
14. Seong, S. Y. & Matzinger, P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nature Rev. Immunol. 4, 469-478 (2004).
15. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotech. 25, 1159-1164 (2007).
16. Bachmann, M. F., Hengartner, H. & Zinkernagel, R. M. Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction. Med. Microbiol. Immunol. 183, 315-324 (1994).
17. Johansen, P. et al. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur. J. Immunol. 35, 3591-3598 (2005).
18. Unanue, E. R. The regulatory role of macrophages in antigenic stimulation. Part two: symbiotic relationship between lymphocytes and macrophages. Adv. Immunol. 31, 1-136 (1981).
19. Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B. & Rock, K. L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA 90, 4942-4946 (1993).
20. + T cell vaccines: it's not rocket science (yet). Curr. Opin. Immunol. 22, 402-410 (2010).
21. Harding, C. V. & Song, R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153, 4925-4933 (1994).
22. Storni, T. & Bachmann, M. F. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J. Immunol. 172, 6129-6135 (2004).
23. Pfeifer, J. D. et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361, 359-362 (1993).
24. + T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 395, 45-55 (2009).
25. Randolph, G. J., Angeli, V. & Swartz, M. A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nature Rev. Immunol. 5, 617-628 (2005).
26. Swartz, M. A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50, 3-20 (2001).
27. Reddy, S. T. , Rehor, A., Schmoekel, H. G., Hubbell, J. A. & Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 11 2 , 26-34 (2006).
28. Oussoren, C., Zuidema, J., Crommelin, D. J. & Storm, G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim. Biophys. Acta 1328, 261-272 (1997). (Pubitemid 27376453)
29. Ono, N., Mizuno, R. & Ohhashi, T. Effective permeability of hydrophilic substances through walls of lymph vessels: roles of endothelial barrier. Am. J. Physiol. Heart Circ. Physiol. 289, H1676-H1682 (2005).
30. Leak, L. V. Studies on the permeability of lymphatic capillaries. J. Cell Biol. 50, 300-323 (1971).
31. Swartz, M. A., Berk, D. A. & Jain, R. K. Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am. J. Physiol. 270, H324-H329 (1996).
32. Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008).
33. Pflicke, H. & Sixt, M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med. 206, 2925-2935 (2009).
34. Bachmann, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448-1451 (1993).
35. Chackerian, B., Lowy, D. R. & Schiller, J. T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108, 415-423 (2001).
36. Jegerlehner, A. et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 32, 3305-3314 (2002).
37. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Tolllike receptors. Nature 416, 603-607 (2002).
38. Jegerlehner, A. et al. TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol. 178, 2415-2420 (2007).
39. Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 438, 364-368 (2005).
40. Eckl-Dorna, J. & Batista, F. D. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 11 3 , 3969-3977 (2009).
41. Bessa, J. et al. Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J. Immunol. 183, 3788-3799 (2009).
42. Sixt, M. et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22, 19-29 (2005).
43. Roozendaal, R. et al. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30, 264-276 (2009).
44. Pape, K. A., Catron, D. M., Itano, A. A. & Jenkins, M. K. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 26, 491-502 (2007).
45. Junt, T. et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450, 110-114 (2007).
46. Phan, T. G., Grigorova, I., Okada, T. & Cyster, J. G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nature Immunol. 8, 992-1000 (2007).
47. Carrasco, Y. R. & Batista, F. D. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27, 160-171 (2007).
48. Wykes, M., Pombo, A., Jenkins, C. & MacPherson, G. G. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. 161, 1313-1319 (1998).
49. Qi, H., Egen, J. G., Huang, A. Y. & Germain, R. N. Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 312, 1672-1676 (2006).
50. Gonzalez, S. F. et al. Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes. Nature Immunol. 11 , 427-434 (2010).
51. Bergtold, A., Desai, D. D., Gavhane, A. & Clynes, R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23, 503-514 (2005).
52. +-dendritic cells and Langerhans cells in HIV-1 transmission. Trends Mol. Med. 14, 12-19 (2008).
53. Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000).
54. Beh, K. J. & Lascelles, A. K. The effect of adjuvants and prior immunization on the rate and mode of uptake of antigen into afferent popliteal lymph from sheep. Immunology 54, 487-495 (1985).
55. Steinman, R. M. et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv. Exp. Med. Biol. 560, 83-97 (2005).
56. Colonna, M., Trinchieri, G. & Liu, Y. J. Plasmacytoid dendritic cells in immunity. Nature Immunol. 5, 1219-1226 (2004).
57. Wollenberg, A. et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. 11 9 , 1096-1102 (2002).
58. - dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685-1696 (2000).
59. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107-111 (2007).
60. Keller, S. A. et al. Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J. Immunol. 184, 26-29 (2010).
61. Villadangos, J. A. & Young, L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 29, 352-361 (2008).
62. Fifis, T. et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148-3154 (2004).
63. Frazer, I. H. et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23, 172-181 (2004).
64. Saveanu, L. et al. IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 325, 213-217 (2009).
65. + dendritic cells. Immunity 30, 544-555 (2009).
66. + T cell responses to influenza. Nature Immunol. 11 , 216-224 (2010).
67. Vollmer, J. & Krieg, A. M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61, 195-204 (2009).
68. Cho, H. J. et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nature Biotech. 18, 509-514 (2000).
69. Storni, T. et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172, 1777-1785 (2004).
70. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nature Rev. Drug Discov. 5, 471-484 (2006).
71. Speiser, D. E. et al. Memory and effector CD8 T-cell responses after nano-particle vaccination of melanoma patients. J. Immunother. 33, 848-858 (2010).
72. Bachmann, M. F. & Zinkernagel, R. M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15, 235-270 (1997).
73. Feldmann, M. & Basten, A. The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J. Exp. Med. 134, 103-119 (1971).
74. Vogelstein, B., Dintzis, R. Z. & Dintzis, H. M. Specific cellular stimulation in the primary immune response: a quantized model. Proc. Natl Acad. Sci. USA 79, 395-399 (1982).
75. Chackerian, B., Lenz, P., Lowy, D. R. & Schiller, J. T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 169, 6120-6126 (2002).
76. Bachmann, M. F. & Dyer, M. R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nature Rev. Drug Discov. 3, 81-88 (2004).
77. Barrington, R., Zhang, M., Fischer, M. & Carroll, M. C. The role of complement in inflammation and adaptive immunity. Immunol. Rev. 180, 5-15 (2001).
78. Carter, R. H. & Myers, R. Germinal center structure and function: lessons from CD19. Semin. Immunol. 20, 43-48 (2008).
79. Dempsey, P. W., Allison, M. E., Akkaraju, S., Goodnow, C. C. & Fearon, D. T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350 (1996).
80. Carter, R. H. & Fearon, D. T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256, 105-107 (1992).
81. Gatto, D. et al. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J. Exp. Med. 201, 993-1005 (2005).
82. Martins, G. & Calame, K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 26, 133-169 (2008).
83. Ochsenbein, A. F. et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286, 2156-2159 (1999).
84. Zinkernagel, R. M. On differences between immunity and immunological memory. Curr. Opin. Immunol. 14, 523-536 (2002).
85. Chisari, F. V. & Ferrari, C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13, 29-60 (1995).
86. Klenerman, P. & Hill, A. T cells and viral persistence: lessons from diverse infections. Nature Immunol. 6, 873-879 (2005).
87. Masopust, D. & Ahmed, R. Reflections on CD8 T-cell activation and memory. Immunol. Res. 29, 151-160 (2004). (Pubitemid 38822405)
88. Kundig, T. M. et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5, 41-52 (1996).
89. Iezzi, G., Karjalainen, K. & Lanzavecchia, A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8, 89-95 (1998).
90. + T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur. J. Immunol. 36, 842-854 (2006).
91. Johansen, P. et al. Antigen kinetics determines immune reactivity. Proc. Natl Acad. Sci. USA 105, 5189-5194 (2008).
92. Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and malignancy. Nature Rev. Immunol. 8, 22-33 (2008).
93. Williams, G. M. & Nossal, G. J. Ontogeny of the immune response. I. The development of the follicular antigen-trapping mechanism. J. Exp. Med. 124, 47-56 (1966).
94. Tew, J. G., Phipps, R. P. & Mandel, T. E. The maintenance and regulation of the humoral immune response: persisting antigen and the role of follicular antigen-binding dendritic cells as accessory cells. Immunol. Rev. 53, 175-201 (1980).
95. Fang, Y., Xu, C., Fu, Y. X., Holers, V. M. & Molina, H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 160, 5273-5279 (1998). (Pubitemid 28267813)
96. Gatto, D. et al. Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J. Immunol. 178, 67-76 (2007).
97. Salk, D. & Salk, J. Vaccinology of poliomyelitis. Vaccine 2, 59-74 (1984).
98. Schijns, V. E. & Degen, W. G. Vaccine immuno-potentiators of the future. Clin. Pharmacol. Ther. 82, 750-755 (2007).
99. Tritto, E., Mosca, F. & De Gregorio, E. Mechanism of action of licensed vaccine adjuvants. Vaccine 27, 3331-3334 (2009).
100. Olafsdottir, T. A., Lingnau, K., Nagy, E. & Jonsdottir, I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand. J. Immunol. 69, 194-202 (2009).
101. Ishii, K. J. & Akira, S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27, 363-371 (2007).
102. Swanson, C. L. et al. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J. Exp. Med. 207, 1485-1500 (2010).
103. Bourquin, C. et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol. 181, 2990-2998 (2008).
104. Vogelzang, A. et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29, 127-137 (2008).
105. Nurieva, R. I. et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29, 138-149 (2008).
106. Bessa, J., Kopf, M. & Bachmann, M. F. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J. Immunol. 184, 4615-4619 (2010).
107. Didierlaurent, A. M. et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186-6197 (2009).
108. Mbow, M. L., De Gregorio, E., Valiante, N. M. & Rappuoli, R. New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411-416 (2010).
109. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S. & Flavell, R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008).
110. Kool, M. et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755-3759 (2008).
111. Li, H., Willingham, S. B., Ting, J. P. & Re, F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21 (2008).
112. Franchi, L. & Nunez, G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38, 2085-2089 (2008).
113. McKee, A. S. et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 183, 4403-4414 (2009).
114. Hansen, B., Sokolovska, A., HogenEsch, H. & Hem, S. L. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 25, 6618-6624 (2007).
115. Hansen, B. et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 27, 888-892 (2009).
116. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
117. + T cell populations lacking helper function. Nature Immunol. 6, 163-170 (2005).
118. Morefield, G. L. et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23, 1588-1595 (2005).
119. Janeway, C. A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13 (1989).